Athersys

Athersys Cash Conversion Cycle

Delisted·Oct 1, 2026

The Cash Conversion Cycle (CCC) of Athersys (ATHXQ) as of Nov 20, 2026 is 74.98. In the previous year, Cash Conversion Cycle (CCC) was 72.80 — a change of 2.99% (higher).

Cash Conversion Cycle

74.98

YoY

2.99%

Last updated:

Cash Conversion Cycle (CCC) of Athersys is 2018 74.98 . Cash Conversion Cycle (CCC) of Athersys was 2017 72.80 . It decreases by 2.99% higher compared to the previous year.

The Athersys Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2014
155.46 USD
Jan 1, 2015
11.00 USD
Jan 1, 2016
12.62 USD
Jan 1, 2017
72.80 USD
Jan 1, 2018
74.98 USD
The Athersys Cash Conversion Cycle history
YEARCash Conversion CycleYoY
74.98+2.99%
72.80+476.77%
12.62+14.79%
11.00-92.93%
155.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Cash Conversion Cycle (CCC) of Athersys is 74.98 in 2018.

Cash Conversion Cycle (CCC) of Athersys changed from 72.80 to 74.98, representing a 2.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Athersys since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Athersys with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Athersys

All Key Metrics — Athersys